Efficacy of cariprazine on predominant negative symptoms of patients with schizophrenia: post hoc analysis of PANSS data, Marder factors, and cognition

被引：7

作者：

Marder, S. ^{[1
]}

Laszlovszky, I. ^{[2
]}

Szalai, E. ^{[2
]}

Szatmari, B. ^{[2
]}

Harsanyi, J. ^{[2
]}

Barabassy, A. ^{[2
]}

Debelle, M. ^{[2
]}

Durgam, S. ^{[3
]}

Bitter, I. ^{[4
]}

Nemeth, G. ^{[2
]}

机构：

[1] Univ Calif Los Angeles, Semel Inst, Sect Psychosis, Los Angeles, CA USA

[2] Gedeon Richter Plc, Med Div, Budapest, Hungary

[3] Forest Res Inst, Clin Dev, Jersey City, NJ USA

[4] Semmelweis Univ, Dept Psychiat & Psychotherapy, Budapest, Hungary

来源：

EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2016年 / 26卷

关键词：

D O I：

10.1016/S0924-977X(16)31595-4

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P.3.d.036

引用

页码：S550 / S550

页数：1

共 50 条

[1] The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors
Fleischhacker, Wolfgang
Galderisi, Silvana
Laszlovszky, Istvan
Szatmari, Balazs
Barabassy, Agota
Acsai, Karoly
Szalai, Erzsebet
Harsanyi, Judit
Earley, Willie
Patel, Mehul
Nemeth, Gyorgy
EUROPEAN PSYCHIATRY, 2019, 58 : 1 - 9
[2] Cariprazine vs risperidone efficacy on predominant negative symptoms of schizophrenia: post hoc analysis of negative symptoms subdomains
Laszlovszky, I.
Barabassy, A.
Szatmari, B.
Harsanyi, J.
Szalai, E.
Nemeth, G.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S902 - S903
[3] Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data
Earley, Willie
Guo, Hua
Daniel, David
Nasrallah, Henry
Durgam, Suresh
Zhong, Yan
Patel, Mehul
Barabassy, Agota
Szatmari, Balazs
Nemeth, Gyorgy
SCHIZOPHRENIA RESEARCH, 2019, 204 : 282 - 288
[4] Efficacy of cariprazine on PANSS items and Marder factors: post hoc analysis of a double-blind, placebo-controlled trial in schizophrenia
Kane, J.
Citrome, L.
Litman, R.
Zukin, S.
Lu, K.
Ruth, A.
Nagy, K.
Laszlovszky, I.
Durgam, S.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S461 - S462
[5] Efficacy of cariprazine in predominant negative symptoms of schizophrenia - post hoc analyses against different comparators
Szatmari, B.
Barabassy, A.
Laszlovszky, I.
Harsanyi, J.
Acsai, K.
Reti-Gyorffy, D.
Earley, W.
Patel, M.
Nemeth, G.
EUROPEAN PSYCHIATRY, 2018, 48 : S105 - S105
[6] Clinical improvement of patients with predominant negative symptoms of schizophrenia: Post-hoc analysis of cariprazine versus risperidone
Sebe, B.
Barabassy, A.
Laszlovszky, I.
Szatmari, B.
Harsanyi, J.
Acsai, K.
Earley, W.
Patel, M.
Nemeth, G.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S275 - S275
[7] The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
Laszlovszky, I.
Dombi, Z. B.
Balogh, A.
Barabassy, A.
Vass, G.
Szatmari, B.
Nemeth, G.
EUROPEAN PSYCHIATRY, 2021, 64 : S533 - S533
[8] Efficacy of cariprazine in the treatment of negative symptoms of schizophrenia: Post hoc analyses versus aripiprazole
Barabassy, A.
Szatmari, B.
Laszlovszky, I.
Harsanyi, J.
Acsai, K.
Sebe, B.
Earley, W.
Patel, M.
Nemeth, G.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S417 - S418
[9] Safety profile of cariprazine in patients with predominant negative symptoms of schizophrenia
Szatmari, B.
Barabassy, A.
Laszlovszky, I.
Harsanyi, J.
Szalai, E.
Reti-Gyorffy, D.
Nemeth, G.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S903 - S903
[10] Efficacy of cariprazine in negative, cognitive, and social function symptoms in schizophrenia: post hoc analysis of a randomized, controlled trial
Cutler, A. J.
Durgam, S.
Lu, K.
Laszlovszky, I.
Szalai, E.
Edwards, J.
Earley, W.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S551 - S552

← 1 2 3 4 5 →